Dyne Therapeutics Inc. (DYN)
NASDAQ: DYN
· Real-Time Price · USD
13.81
-0.60 (-4.16%)
At close: Jun 16, 2025, 3:59 PM
15.00
8.65%
After-hours: Jun 16, 2025, 07:59 PM EDT
-4.16% (1D)
| Bid | 13.78 |
| Market Cap | 1.57B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -367.13M |
| EPS (ttm) | -3.61 |
| PE Ratio (ttm) | -3.82 |
| Forward PE | -3.83 |
| Analyst | Buy |
| Ask | 15 |
| Volume | 1,595,210 |
| Avg. Volume (20D) | 2,523,606 |
| Open | 14.47 |
| Previous Close | 14.41 |
| Day's Range | 13.71 - 14.61 |
| 52-Week Range | 6.36 - 47.45 |
| Beta | 1.16 |
Analyst Forecast
According to 0 analyst ratings, the average rating for DYN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+20.21%
Dyne Therapeutics shares are trading higher. The c...
Unlock content with
Pro Subscription
1 month ago
-15.3%
Shares of vaccine and gene therapy stocks are trading lower after FDA Commissioner Marty Makary reportedly named Vinay Prasad as director of the Center for Biologics and Research.
3 months ago · seekingalpha.com
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate BiomarkerPositive biomarker and functional data released from phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1. Data from registration cohort phase 1/2 ACHIEVE study, us...